MEMORANDUM AND ORDER REGARDING EMERGENCY MOTION FOR RECONSIDERATION OF PRELIMINARY INJUNCTION ORDER (Dkt. No: 144)
PONSOR, District Judge.I. INTRODUCTION
This case arises out of a Supply and Distribution Agreement in which Defendant Biolitec, Inc. (“BI”), a subsidiary of Defendant Biolitec AG (“BAG”), agreed to defend and indemnify Plaintiff AngioDynamics, Inc. against any third-party patent infringement claims arising out of the marketing and distribution of Defendants’ products. In separate (now successful) litigation before a federal judge in the Northern District of New York, Plaintiff charged that, when Defendants learned of the steep cost of defending Plaintiff against such claims, they failed to honor their promise and abandoned Plaintiff.
In this litigation, Plaintiff charges that Defendant BAG looted Defendant BI, draining more than $18 million out of the company. This fraudulent transfer of funds had the effect of undermining BI’s ability to defend and indemnify Plaintiff and rendered BI judgment-proof against any judgment Plaintiff might obtain against BI for breaking its promise. Plaintiffs claims before this court include, inter alia, tortious interference with contract, piercing the corporate veil, fraudulent transfer in violation of Mass. Gen. Laws ch. 109A, and unfair and deceptive acts or practices in violation of Mass. Gen. Laws ch. 93A, § 11.
Defendants initially moved to dismiss Plaintiffs claims under Fed.R.Civ.P. 12(b)(2) for lack of personal jurisdiction and Fed.R.Civ.P. 12(b)(6) for failure to state a claim. (Dkt. No. 13.) On July 25, 2011, this court denied Defendants’ motion. (Dkt. No. 53.)
In August 2012, Plaintiff became aware that Defendant BAG was planning a merger with its Austrian subsidiary. Plaintiff filed for a preliminary injunction to prevent Defendant BAG from completing the merger. Plaintiff alleged that the merger would place the company’s assets out of its reach, as American judgments are unen*349forceable in Austria. On August 29, Judge Rya W. Zobel ordered entry of the preliminary injunction in the form requested by Plaintiff, pending a further hearing by the undersigned.
On September 13, 2012, following a hearing, this court itself reaffirmed the preliminary injunction as previously entered by Judge Zobel. The injunction had the effect of forestalling BAG’S planned merger until the court entered a final judgment in this case. At the September 13 hearing, this court noted that Defendants could file a motion for reconsideration or for an evidentiary hearing. The current Motion for Reconsideration (Dkt. No. 144) was promptly filed by Defendants. For the reasons stated below, Defendants’ motion will be denied.
II. BACKGROUND
In its memorandum and order on Defendants’ motion to dismiss, this court laid out the detailed relationship among the parties. AngioDynamies, Inc. v. Biolitec, Inc., 2011 WL 3157312, *1-2 (D.Mass. July 25, 2011). Since this ruling, several events have enriched the factual environment.
First, in the last sixteen months, the federal district court for the Northern District of New York granted summary judgment, on the question of liability, in favor of AngioDynamies and against Defendant BI, the American subsidiary of BAG. BI was obligated to provide reimbursement of settlement and defense costs that AngioDynamics incurred defending itself in patent infringement litigation. Some months later, the New York court entered judgment against BI, on the question of damages, in favor of AngioDynamies in the amount of $16,463,846.94 plus pre-judgment interest. (Dkt. No. 157, Reynolds Decl. 1-2.)
After the grant of summary judgment in the New York action, Plaintiff became aware that Defendant BAG, Bl’s parent company, planned to complete a merger with its Austrian subsidiary entity, Biolitec Unternehmensbeteiligungs IAG (“BUIAG”). Defendant BAG set a shareholders’ meeting for August 30, 2012, to vote on the proposed merger of BAG into BUIAG. Following the proposed merger, BUIAG would hold all assets and liabilities previously held by BAG, and shareholders in BAG would have their shares converted into shares of BUIAG. BAG publicly announced that the -75% ownership share of CEO Wolfgang Neuberger (also a defendant in this action) in BAG guaranteed that his plan would be approved by a majority of the' shareholders.
On August 29, 2012, as noted above, Judge Zobel granted Plaintiffs Motion for a TRO and Preliminary Injunction to bar this merger. The injunction restrained Defendants from:
• “carry[ing] out the proposed ‘downstream merger’ of Biolitec AG with its Austrian subsidiary;
• “alienat[ing], disposing] of, selling] dissipating], encumbering], or otherwise transfer[ing] any ownership interest it holds in any other defendant during the duration of this Order; and
• “alienating], disposing] pf, selling] dissipating], encumbering], or otherwise transfer[ing] any interest it may have in any property during the duration of this Order, except that this Order shall not preclude the defendants from taking such actions as are reasonable and necessary to the ongoing and continued operation of the business of Biolitec, Inc., Biolitec AG, and Biomed Technology Holdings, Ltd. in the ordinary course of business, including the payment of reasonable attorneys’ fees for the provision of legal services; and except that this Order shall not apply to the reasonable and necessary per*350sonal and living expenses of defendant Wolfgang Neuberger.
(Dkt. No. 126.) The injunction further restrained, with exceptions, Defendants’ use of their property pending a further order of the court.
On September 6, 2012, defense counsel informed the court that, despite Judge Zobel’s order, Defendant BAG had proceeded with the shareholders’ meeting and vote. (Dkt. No. 133 ¶ 5.) Defendants did not inform the minority shareholders of the TRO. (Dkt. No. 136-1, Sept. 10, 2010 Reynolds Decl. ¶ 11.) The vote in favor of the merger passed by a wide margin.
The convening of the shareholders’ meeting, despite the preliminary injunction, raised troubling questions about Defendants’ good faith. Before Judge Zobel, Defendants had argued passionately that the injunction requested by Plaintiff would bar the shareholders’ meeting, with catastrophic results for BAG. Indeed, this was Defendants’ primary line of argument in opposing Plaintiffs motion and demonstrating irreparable harm to them. Despite this, as soon as Judge Zobel’s order entered, Defendant BAG proceeded with the supposedly forbidden shareholders’ meeting in any event.
When counsel appeared before this court on September 13, 2012, for argument on whether Judge Zobel’s order should be extended, Defendants entirely reversed their position regarding the shareholders’ meeting. Now they argued that Judge Zobel’s order did not, in fact, prohibit the shareholders’ meeting or the vote in favor of the merger, because “neither the meeting nor the vote resulted in the ‘carrying out’ of the merger or the ‘alienation, exchange, disposal, sale, dissipation, encumbering, or other transfer’ of any ownership interest in Biolitec AG or any other defendant.” (Dkt. No. 133 ¶ 4.) Defendants contended that the merger, though voted on, would not in fact be carried out until it was approved by German and Austrian courts and recorded in the companies’ official registers. (Dkt. No. 133 ¶ 4.) Plaintiff challenged the actions of Defendant BAG, as the vote “committ[ed] the company to the very action that this Court has specifically enjoined, and mov[ed] that action forward toward completion.” (Dkt. No. 136, Pl.’s Suppl. Memo. 12.)
•Regardless of the substantive effect of the shareholders’ vote — it appears that, despite the vote, the formal merger of BAG into the Austrian entity has not yet occurred — Defendants’ about-face is disturbing.- To foretell dire consequences if an injunctive order issues, in order to persuade a judge not to issue the order, and then simply proceed with no negative consequences whatsoever after the order issues, is not the most credible way to oppose a motion for preliminary injunction or to reassure a court as to a party’s good faith.
On September 13, 2012, after hearing oral argument, this court .reaffirmed the preliminary injunction entered by Judge Zobel. (Dkt. No. 141.) This court’s rationale for this ruling may be summarized as follows.
First, at the hearing Plaintiff demonstrated a likelihood success on the merits. As noted, AngioDynamics now has a verdict well in excess of $16,000,000 against Defendant BI. Strong evidence, including an insider affidavit, supported Plaintiffs contention that Defendant BAG looted assets from BI in order to insure that BI would be judgment-proof. It is conceded by Defendants that the transfers from BI to BAG have in fact had this effect:1 BI now lacks the assets to pay the judgment Plaintiff obtained in the Northern District of New York. Based on this conduct, it is likely that Plaintiff will eventually obtain a judgment in this court against both BI and BAG, as well as the other Defendants.
*351Second, Plaintiff demonstrated irreparable harm that will flow from the proposed merger. Under German law, Plaintiff has a fair chance of enforcing an American judgment against BAG. The task of doing this may be formidable, but it is not impossible. Under Austrian law, the parties agree that it would be flatly impossible to enforce any American judgment against BAG. Once the merger occurs moving all of BAG’S assets from Germany to Austria, any further litigation in this court against BAG would be pointless. Since BI now appears to be judgment-proof, Plaintiff is primarily looking to BI assets. held by BAG to satisfy the judgment of the New York federal court. The merger would place BAG assets utterly out of Plaintiffs reach.
Third, the balance of harm strongly favors Plaintiff. The inconvenience suffered by BAG in postponing its merger for a few months while this case is resolved amounts to very little in comparison with the harm Plaintiff would suffer in losing any opportunity to recover against BAG.
At the September 13 hearing, the court, as noted, entertained oral argument only, based on extensive written submissions. During argument, Defendants’ counsel made reference to factual materials not before the court to oppose Plaintiffs motion and suggested that an evidentiary hearing might persuade the court to withdraw the prehminary injunction. In light of these representations, the court’s September 13 ruling was entered without prejudice to a request for reconsideration, with further written submissions and possible oral testimony.
On September 18, 2012, Defendants moved for reconsideration of the preliminary injunction and requested an evidentiary hearing. (Dkt. No. 144.) On November 20, 2012, the court once more heard argument on the question of whether the preliminary injunction should stand or, alternatively, whether Defendants were entitled to an evidentiary hearing. For the reasons set forth below, the court will decline to reconsider the preliminary injunction. Moreover, since nothing in an evidentiary hearing has any prospect of altering the court’s ruling, the court will also deny Defendants’ request for a hearing.
III. DISCUSSION
“A plaintiff seeking a preliminary injunction must establish that he is likely to succeed on the merits, that he is likely to suffer irreparable harm in the absence of preliminary relief, that the balance of equities tips in his favor, and that an injunction is in the public interest.” Winter v. Natural Resources Defense Council, 555 U.S. 7, 20, 129 S.Ct. 365, 172 L.Ed.2d 249 (2008). As laid out below, a series of undisputed facts provide sufficient support for Plaintiffs motion for preliminary injunction.
A. Undisputed Facts relating to the Injunction.
At the risk of repetition, the following facts are clear. First, Plaintiff has obtained a judgment of over $20 million (including interest) against • co-Defendant BI for breach of contract related to the reimbursement of settlement and defense costs from patent infringement lawsuits. BI is now insolvent, and Defendants concede that BI does not have sufficient resources to satisfy the judgment granted to AngioDynamics.
Second, Defendants BAG, Wolfgang Neuberger, and Biolitec Medical Holdings, Ltd., moved substantial monies from BI during the time when the New York litigation was pending. While the purpose of these transfers is disputed, neither party disputes that assets were moved- out of BI to BAG and other related entities.
*352Third, if Defendant BAG is allowed to shift its assets to Austria, this litigation would become pointless. Both parties agree that U.S. judgments in commercial matters cannot be enforced in Austria.
Fourth, enforcing a judgment in Germany may be difficult but it is not impossible.
Finally, Plaintiff has provided the sworn affidavit of a corporate insider, Stefan Spaniol, which directly confirms that Neuberger diverted assets from BI to BAG and other related entities with the specific intent to thwart collection of the American judgment obtained by Plaintiff against BI in the Northern District of New York. While the Spaniol declaration is not beyond impeachment, it is rare to have such a powerful insider statement supporting a plaintiff in a fraud case.
Under these circumstances, all of the preliminary injunction factors strongly favor Plaintiff.
B. Preliminary Injunction Factors.
1. Likelihood of Success on the Merits.
To establish a likelihood of success on the merits, the district court must only determine the “probable outcomes.” Jimenez Fuentes v. Torres Gaztambide, 807 F.2d 236, 238 (1st Cir.1986). In the First Circuit, the movant’s likelihood of success is particularly important in determining whether a preliminary injunction is proper. See, e.g., Cohen v. Brown Univ., 991 F.2d 888, 903 (1st Cir.1993); Lancor v. Lebanon Housing Auth., 760 F.2d 361, 362 (1st Cir.1985).
Here, the parties have yet to finish discovery. However, both sides have drawn on affidavits, documents shared in discovery, and depositions. Also, to Plaintiffs chagrin, Defendants have occasionally relied on documents that have yet to be shared with Plaintiff in discovery.1
For each claim “the burdens at the preliminary injunction stage track the burdens at trial.” Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal, 546 U.S. 418, 429, 126 S.Ct. 1211, 163 L.Ed.2d 1017 (2006). Here, Plaintiff has five claims for relief. Only two of these counts— piercing the corporate veil and fraudulent conveyance — provide claims for equitable relief that would justify a preliminary injunction. Plaintiff is likely to succeed on several of its claims of fraudulent conveyance. The piercing the corporate veil claim is more complex, but even on this claim, Plaintiff has provided substantial evidence to bolster its allegations — notably the Spaniol declaration confirming the fraud. At this stage, it is enough that Plaintiff has demonstrated likelihood of success on at least some of its claims.
a. Fraudulent Conveyance.
The Massachusetts fraudulent transfer statute gives creditors access to relief against transfers which meet the statutory definition as fraudulent:
(a) A transfer made or obligation incurred by a debtor is fraudulent as to a creditor, whether the creditor’s claim arose before or after the transfer was made or the obligation was incurred, if the debtor made the transfer or incurred the obligation:
(1) with actual intent to hinder, delay, or defraud any creditor of the debtor.
Mass. Gen. Laws ch. 109A, § 5.
The First Circuit has recognized that “[i]t is often impracticable, on direct evidence, to demonstrate an actual intent to hinder, delay, or defraud creditors.” Max Sugarman Funeral Home, Inc. v. ADB Investors, 926 F.2d 1248, 1254 (1st *353Cir.1991). The First Circuit has set out five factors to assess:
(1) actual or threatened litigation against the debtor; (2) a purported transfer of all or substantially all of the debtor’s property; (3) insolvency or other unmanageable indebtedness on the part of the debtor; (4) a special relationship between the debtor and the transferee; (5) retention by the debtor of the property involved in the putative transfer.
ADB Investors, 926 F.2d at 1254. The confluence of several of these factors can “constitute conclusive evidence of an actual intent to defraud, absent ‘significantly clear’ evidence of a legitimate supervening purpose.” ADB Investors, 926 F.2d at 1254-55; see also FDIC v. Anchor Props., 13 F.3d 27, 32 (1st Cir.1994).
Defendant BI satisfies all these criteria, on largely undisputed evidence. As to the first factor, actual or threatened litigation, actual litigation against Defendant BI by Plaintiff was first filed in New York in January 2008. (Dkt. No. 7-1, Am. Compl. Ex. A.) The action before this court was filed in October 2009. (Dkt. No. 1, Pl.’s Compl.) The patent infringement litigation against AngioDynamies — for which BI was contractually obligated to indemnify AngioDynamies — began in 2004.
On the second factor, purported transfer of all or substantially all of debtor’s property, the tax records of Defendant BI show that its assets have decreased from $24,985,600 in 2008 to $10,899,835 in 2011. In 2011, BI also reported $15,761,133 in “intercompany debt” to other Biolitec group companies. (Dkt. No. 136-4, Sept. 10, 2010 Reynolds Deck ¶ 2, Ex. A, B.) This history provides strong support of substantial transfers.
The third factor, insolvency, is largely undisputed.' BI has had “poor economic results” according to Defendants’ declarations. (Dkt. No. 118-1, Meyersie Deck ¶ 19). Defendants’ accountants indicated that BI could be subject to a “going concern qualification.” (Dkt. No. 111-2, Aug. 21, 2012 Reynolds Deck Ex. C.)2
Fourth, the transfers in question were all to entities that had a special relationship with BI. All of the entities are part of the Biolitec group of companies. Defendant Neuberger remains the CEO and dominant shareholder of debtor and all transferees.
Finally, because the transfers are all between Neuberger-controlled entities, the debtor has retained the property that was transferred, the fifth indicia of a fraudulent transfer. Many of the transfers in question involve a change in legal title but no change in the location of assets. Defendants created holding companies and simply recharacterized ' debt. Defendants have not sold assets or debt to third parties but have instead transferred assets and liabilities within their family of companies.
In sum, Plaintiff has made out the prima facie case for fraudulent conveyance. None of these factors alone would necessarily indicate .a fraudulent transfer. But taken together these factors should “constitute conclusive evidence of an actual intent to defraud.” ADB Investors, 926 F.2d at 1255.
Given this showing, the burden shifts to Defendants to show “significantly clear ev*354idence of a legitimate supervening purpose.” ADB Investors, 926 F.2d at 1255. Defendants argue, incorrectly, that Plaintiffs failure to come forward with evidence of specific fraudulent transfers is fatal to its request for preliminary relief. This argument misapprehends the allocation of the burden, which Defendants, not Plaintiff, must bear once an initial showing is made based on the ADB Investors factors.
It is true the Defendants have provided some documentation for many of the disputed transfers. However, much of the documentation sets out the amounts of the transfers and the parties involved but gives little information about the purpose of the transfers or whether fair consideration was given. As spelled out below, on several of the fraudulent conveyance claims, Defendants have failed to provide significant evidence of a legitimate supervening purpose as required by Massachusetts law. Some examples make this clear.
• Sale of patents to a sister company.
In their complaint, Plaintiff alleged that Defendant BAG transferred patents worth more than $1 million from BI to Biolitec Pharma Marketing Ltd. (which is solely owned by BAG) without any compensation in return and for no legitimate business purpose in March 2009. Plaintiffs insider, Stefan Spaniol, stated in his declaration that Wolfgang Neuberger specifically talked with him about removing patents from the United States to protect them from potential U.S. judgments.
Defendants provided the declaration of BI CFO Art Henneberger to explain many of the transfers and provide documentation about the costs. In the patent context, Henneberger stated that BAG decided to consolidate the ownership of patents and other intellectual property in the Group’s Malaysian affiliate. The invoices for the transfer are provided and BI received over $1 million in exchange for the patents.
This information falls far short of “significantly clear” evidence of a legitimate supervening purpose. While consolidation of patents may have some legitimate purpose in theory, the transfer may have also been done to place all of the patents in a jurisdiction, Malaysia, where they could not be reached by creditors. More significantly, the bare invoices provide no evidence that the amount paid to BI was fair consideration for the assets.
• Allocation of Overhead Expenses to Foreign Subsidiaries
Plaintiff alleged that Defendants allocated overhead expenses to BI, its American subsidiary, that were not charged to other foreign subsidiaries. The Spaniol declaration supports this allegation.3 Defendants contended that these overhead costs are for research and development and general administration. Defendants claimed that they started charging BI for overhead costs only when “the U.S. market had reached a level of maturity that would enable the U.S. subsidiary to bear a portion of the overhead expenses on a regular basis without undue effect on further market development.” (Dkt. No. 144-3, Henneberger Deck $ 15.) In the last fiscal year, the company has, for the first time, begun charging overhead costs to other *355foreign subsidiaries in the Middle East, Ireland, and Italy.
On the issue of allocating overhead, however, Defendants have not provided any standard, uniformly applied, formula for determining overhead expenses. Indeed, Defendant BI’s CFO Henneberger testified in another case that he did not know what the formula was, if it had ever actually been utilized, or what it included. . BI’s accountants have also raised issues about the allocation of corporate charges to BI and requested “assurance that these costs are allocated to all subsidiaries/related parties.” (Dkt. No. 136-7 at 11.)
In sum, the record is devoid of documentation showing how a determination was made as to the timing and amount of overhead cost allocations. At this stage, a significantly clear legitimate reason for the transfer has not been presented.
• Pricing on urology lasers
Plaintiff also alleged that Defendants unjustifiably increased the -price they charged BI for urology lasers from $25,000 to $50,000 in 2006. Defendants conceded that the price doubled in 2006, but they argued that the cost to manufacture the lasers was close to $25,000 and it made sense to sell the lasers to BI for $50,000 given that BI sold the same lasers retail for $87;500 to $100,000.
Defendants have attached emails and invoices which show that Kelly Moran, the COO of BI at the time, was aware of this increased price and continued to purchase a large number of lasers (including one invoice in October, 2006, in which BI ordered 60 lasers at $50,000 each). Defendants now claimed that the U.S. market for the lasers had matured to a point where BAG could charge BI more for the wholesale lasers.
The email exchanges between Moran and Neuberger, which Defendants rely on heavily, actually show that Moran questioned the charge of $50,000 and recommended using a billing number that more accurately- represented the cost. The email exchange also noted that the cost was around $25,000. The final decision on price was made by Defendant Neuberger despite the protests from BI. There is nothing in the email exchange that sets out the rationale for the price increase as “market maturation.” At the hearing on this motion, Plaintiff also provided invoices for the same urology lasers that were being sold to the American subsidiary BI for $50,000 and to a European subsidiary for 25,000 on the same day.
• Challenged Invoices including FOS-CAN Consulting Charges
Plaintiff alleged that Defendant BAG issued $3,668,192 in false and fraudulent invoices to BI. Approximately $3.4 million (93.1%) of these were issued starting March 29, 2004 — after Plaintiff was sued in 2004 for patent infringement. Plaintiff pointed out that Defendants have only attempted to explain one category of these invoices — charges for FOSCAN consulting — which only accounted for only $1.26 million of the challenged invoices. Plaintiff also questioned the legitimacy of the FOSCAN consulting charges.
Defendants explained that BI was attempting to obtain FDA approval for FOS-CAN, a pharmaceutical used in conjunction with the Company’s laser medical procedure. Defendants argued that Biolitec Pharma (Ireland) Limited was the company responsible for developing and testing FOSCAN. Defendants contended that BI paid Biolitec Pharma to provide consulting services on FDA approval. Defendants provided a consulting agreement and invoices. BI paid Biolitec Pharma $50,000 per month between July 1, 2006, and June 30, 2008, for consulting services.
*356Again, this evidence is weak. The consulting agreement presented by Defendants was neither signed nor dated. It is not clear when this document was produced or if this was the agreement that governed the contract.
These four examples amply demonstrate the likelihood that Plaintiff has to succeed on its fraudulent transfer claims. Plaintiff points to transfers detrimental to BI in many other areas — intercompany debt, interest charges, Neuberger’s salary and personal loans from BI, and legal expenses. It is unnecessary for the court to address these other areas at this time. It is clear that Defendants’ efforts fall short of providing significantly clear evidence of a legitimate supervening purpose as required by ADB Investors.
b. Piercing the Corporate Veil.
In the seminal case of My Bread Baking Co. v. Cumberland Farms, Inc., 353 Mass. 614, 233 N.E.2d 748, 752 (1968), the Massachusetts Supreme Judicial Court (“SJC”) set forth a two-pronged test for determining when a plaintiff may pierce the corporate veil:
(a) when there is active and direct participation by the representatives of one corporation, apparently exercising some form of pervasive control, in the activities of another and there is some fraudulent or injurious consequence of the intercorporate relationship, or (b) when there is a confused intermingling of activity of two or more corporations engaged in a common enterprise with substantial disregard of the separate nature of the corporate entities, or serious ambiguity about the manner and capacity in which the various corporations and their respective representatives are acting.
Id. (emphasis added). More recently, the SJC refined this test by establishing twelve factors (referred to by the parties as the “Pepsi factors”) for courts to consider:
(1) common ownership; (2) pervasive control; (3) confused intermingling of business assets; (4) thin capitalization; (5) nonobservance of corporate formalities; (6) absence of corporate records; (7) no payment of dividends; (8) insolvency at the time of the litigated transaction; (9) siphoning away of corporation’s funds by dominant shareholder; (10) nonfunctioning of officers and directors; (11) use of the corporation for transactions of the dominant shareholders; and (12) use of the corporation in promoting fraud.
Flatten, 437 F.3d at 128 (quoting Attorney Gen. v. M.C.K., Inc., 432 Mass. 546, 736 N.E.2d 373, 380 n. 19 (2000)). The analysis of these factors does not involve merely counting the ones favoring veil-piercing and the ones against it; a court must “examine[] the twelve factors to form an opinion whether the over-all structure and operation misleads.” Evans v. Multicon Const. Corp., 30 Mass.App.Ct. 728, 574 N.E.2d 395, 400 (1991) (piercing corporate veil when four factors favored veil-piercing and eight opposed it).
In its order denying Defendants’ motion to dismiss, the court emphasized that “the complaint sets forth a textbook example of the ‘rare situation[ ]’ in which disregard of the corporate form is warranted.” AngioDynamics, Inc. v. Biolitec, Inc., 2011 WL 3157312, *6 (D.Mass. July 25, 2011). The court found it “particularly noteworthy that Plaintiffs allegations here satisfy almost every factor presented by the SJC, with the possible exceptions of non-payment of dividends and insolvency.” Id.
In its filings in support of the motion for preliminary injunction, Plaintiff added several new pieces of evidence. Most notably, Plaintiff presented the declaration of Ste*357fan Spaniol, the former Managing Director of CeramOptec GmbH, the primary manufacturing entity of the Biolitec Group, and former member of the executive board at BAG. In his declaration, Spaniol confirmed many of Plaintiffs allegations that Neuberger intended to move assets out of BI to make it incapable of paying any judgment awarded to AngioDynamics.
Piercing the corporate veil is often a difficult claim to make out. As the First Circuit has noted, Massachusetts law sets up a “presumption of corporate ^separateness,” which may be overcome only in rare situations. Platten v. HG Bermuda Exempted Ltd., 437 F.3d 118, 129 (1st Cir.2006). But here Plaintiff has continued to provide evidence that supports its- initial allegations. At this stage, Plaintiff is hot required to demonstrate a certainty of success, only a probability. The quantum of evidence offered is sufficient to reach this level on the count seeking to pierce the corporate veil. Defendants have been able to do no more than dilute a few of Plaintiffs claims — many of which still tend to show that BAG unjustifiably diverted substantial assets from BI during the relevant time period.
2. Irreparable Harm.
The merger would mean that BAG would cease to exist and its assets and liabilities would become the property of BUIAG in Austria. As noted, the merger to the subsidiary in Austria would make enforcement of a judgment against BAG simply impossible. As both parties concede, “U.S. judgments in commercial matters cannot be recognized or enforced in Austria.” (Dkt. No. 136-2, Baumgartner Decl. ¶ 4.)
Defendants do not argue that it would be possible to enforce a judgment in Austria. Instead, they contend that AngioDynamics would also face the same impossible burden of re-litigating its substantive tort claims in a German enforcement proceeding. (Dkt. No.-144, Defs.’ Mot. Reconsideration 2.)
Both sides have submitted extensive materials from European law academics and practitioners on this issue. In this blizzard of submissions, two points remain clear: (1) allowing BAG to shift assets to Austria would make this litigation pointless, as enforcement in Austrian courts is not possible; and, (2) enforcing a judgment against BAG in Germany might (or might not) be difficult but it is not impossible. In other words, there is some chance of enforcing this court’s judgment in Germany, but no chance in Austria. Plaintiff would be irreparably harmed if the court allowed BAG to transfer its assets to Austria.
3. Balance of Harm.
The balance of harm also favors Plaintiff here. Plaintiff stands to lose its entire case if BAG transfers its assets to Austria. In comparison, BAG stands' to lose very little by holding off on the merger until after this litigation is completed.4
Defendants have pointed to, some business reasons for the move — more favorable corporate tax and labor laws, a move to a preferred stock exchange listing, and proximity to a growing market in Eastern Europe and Russia. However, not all of these reasons justify moving the headquarters and assets of BAG into BUIAG. BAG no longer has any employees and already maintains a regional office in Austria that deals with the Eastern European market. (Dkt. No. 123, Pl.’s Reply Mem. 3, 5.) Indeed, Defendants had successfully increased their sales in Eastern Europe by approximately 370% in one year while *358BAG headquarters were located in Germany. (Dkt. No. 118-3, Sagnak Deck ¶ 5.)
Two of the business reasons for the move do seem to be threatened by the preliminary injunction: the stock classification move to the Entry Standard segment and tax advantages for BAG assets. But on both accounts, Defendant BAG does not appear to be faced with an irreparable injury. When the injunction is lifted, the company can proceed with the merger at that time. Plaintiff stands to lose their entire case plus possible enforcement of their New York judgment if the merger occurs. Defendants merely face a delayed realization of a business opportunity. The harm to Plaintiff emphatically outweighs the harm to Defendants.
4. Public Interest.
Finally, an injunction is in the public interest. Plaintiff has obtained a judgment against Defendant BI in the Northern District of New York. Defendants concede that BI cannot satisfy that judgment. If BAG and the other Defendants have illegitimately looted assets from BI, the assets of the other Defendants should be available to Plaintiff to satisfy its judgment. Preserving the status quo to maintain the possibility of enforcement is in the public interest.
IV. CONCLUSION
For the foregoing reasons, the Defendants’ motion for reconsideration and for an evidentiary hearing (Dkt. No. 144) is hereby DENIED. The case will proceed, subject to the injunction, in accordance with the scheduling order previously entered.
It is So Ordered.
. As Plaintiff pointed out, Defendants have been less than -forthcoming in discovery and have been subject to successful motions to compel. (Dkt. No. 171, PL's Sur-Reply 16.)
. Defendants spend much of' their briefing explaining that BI’s poor performance since 2008 is due to the poor management of the former Chief Operating Officer and mounting legal bills. (See, e.g., Dkt. No. 162, Defs.’ Reply 5-6.) However, the First Circuit’s test does not ask whether there is a justifiable insolvency. Instead, thin capitalization or insolvency — regardless of reason — is one of several factors that is weighed to determine whether a fraudulent transfer should be inferred.
. "[Neuberger] also specifically talked with me about imposing overhead charges and/or corporate cross-charges from Biolitec AG onto Biolitec, Inc. for the purpose of pulling money out of Biolitec, Inc. Neuberger specifically discussed with me that these charges were not being equally imposed on all other subsidiary entities that were located outside of the United States. As an executive of the Biolitec group, I saw that these overhead charges were in fact imposed on Biolitec, Inc. and did in fact deplete the assets of Biolitec, Inc.” (Dkt. No. 123-1, Second Spaniol Deck $4.)
. At this time, trial is scheduled for June 2013.